Your browser is no longer supported. Please, upgrade your browser.
Seres Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.23 Insider Own9.07% Shs Outstand91.53M Perf Week-2.25%
Market Cap628.14M Forward P/E- EPS next Y-1.02 Insider Trans0.00% Shs Float83.36M Perf Month-67.12%
Income-104.70M PEG- EPS next Q-0.37 Inst Own94.80% Short Float7.41% Perf Quarter-67.60%
Sales30.70M P/S20.46 EPS this Y10.00% Inst Trans1.70% Short Ratio4.42 Perf Half Y-73.64%
Book/sh1.57 P/B4.43 EPS next Y20.30% ROA-37.90% Target Price- Perf Year70.17%
Cash/sh2.69 P/C2.59 EPS next 5Y- ROE-95.00% 52W Range4.09 - 38.50 Perf YTD-71.59%
Dividend- P/FCF- EPS past 5Y13.70% ROI-44.10% 52W High-81.97% Beta3.96
Dividend %- Quick Ratio5.30 Sales past 5Y- Gross Margin- 52W Low69.68% ATR1.45
Employees155 Current Ratio5.30 Sales Q/Q-30.50% Oper. Margin- RSI (14)19.11 Volatility8.32% 8.84%
OptionableYes Debt/Eq0.18 EPS Q/Q-38.00% Profit Margin- Rel Volume2.82 Prev Close6.96
ShortableYes LT Debt/Eq0.15 EarningsAug 03 BMO Payout- Avg Volume1.40M Price6.94
Recom1.90 SMA20-52.55% SMA50-62.71% SMA200-69.99% Volume1,484,219 Change-0.29%
Jul-23-21Downgrade Goldman Neutral → Sell $24 → $7
May-18-21Resumed Goldman Neutral $24
Mar-05-21Upgrade Chardan Capital Markets Neutral → Buy $30
Sep-18-20Downgrade Chardan Capital Markets Buy → Neutral $32.50 → $27.50
Aug-18-20Initiated Piper Sandler Overweight $40
Aug-11-20Upgrade Jefferies Hold → Buy $4 → $29
Aug-11-20Reiterated H.C. Wainwright Buy $8 → $41
Apr-30-19Initiated Jefferies Hold $7
Oct-22-18Initiated Chardan Capital Markets Buy $15
Oct-13-17Initiated Oppenheimer Outperform $19
Aug-04-17Reiterated H.C. Wainwright Buy $15 → $19
Feb-01-17Reiterated FBR & Co. Outperform $23 → $18
Aug-12-16Reiterated FBR Capital Outperform $43 → $23
Aug-01-16Reiterated H.C. Wainwright Buy $50 → $15
Aug-01-16Downgrade BofA/Merrill Buy → Neutral
Jul-29-16Resumed H.C. Wainwright Buy $50
Mar-30-16Initiated FBR Capital Outperform $40
Mar-03-16Initiated Guggenheim Buy
Jan-25-16Initiated H.C. Wainwright Buy $55
Oct-22-15Upgrade BofA/Merrill Neutral → Buy
Aug-03-21 08:45AM  
Jul-29-21 07:00AM  
Jul-28-21 01:51PM  
Jul-23-21 06:12AM  
Jul-22-21 11:51AM  
Jul-21-21 12:01PM  
Jul-20-21 03:02PM  
Jul-07-21 08:36AM  
Jul-02-21 01:45PM  
Jul-01-21 11:01AM  
Jun-14-21 07:51PM  
Jun-10-21 07:00AM  
Jun-04-21 02:30PM  
Jun-01-21 08:00AM  
May-25-21 08:00AM  
May-21-21 12:15PM  
May-20-21 08:00AM  
May-19-21 05:22PM  
May-12-21 07:00AM  
May-11-21 08:00AM  
May-09-21 04:10AM  
May-04-21 08:20AM  
Apr-30-21 03:59PM  
Apr-28-21 07:00AM  
Apr-15-21 07:00AM  
Mar-30-21 09:30AM  
Mar-12-21 07:00AM  
Mar-08-21 07:00AM  
Mar-05-21 10:29AM  
Mar-02-21 08:15AM  
Feb-26-21 08:00AM  
Feb-24-21 07:00AM  
Feb-10-21 03:52AM  
Jan-23-21 11:30PM  
Jan-19-21 07:00AM  
Jan-14-21 12:27PM  
Jan-06-21 07:00AM  
Dec-23-20 10:07AM  
Dec-22-20 09:48AM  
Dec-15-20 06:35AM  
Dec-12-20 03:13PM  
Dec-11-20 06:45AM  
Nov-20-20 07:15AM  
Nov-19-20 07:00AM  
Nov-12-20 06:17AM  
Nov-11-20 09:04AM  
Nov-09-20 04:00PM  
Nov-06-20 07:00AM  
Nov-02-20 07:00AM  
Oct-22-20 07:00AM  
Oct-12-20 07:00AM  
Oct-01-20 01:00PM  
Sep-22-20 07:00AM  
Sep-14-20 07:00AM  
Sep-11-20 07:00AM  
Aug-21-20 02:24PM  
Aug-18-20 09:48AM  
Aug-17-20 04:15PM  
Aug-13-20 06:31PM  
Aug-12-20 09:39PM  
Aug-11-20 06:38PM  
Aug-10-20 03:52PM  
Aug-07-20 08:55AM  
Jul-28-20 12:33PM  
Jul-08-20 10:06AM  
Jul-07-20 08:56AM  
Jun-25-20 11:23AM  
Jun-22-20 07:00AM  
Jun-07-20 06:24PM  
Jun-02-20 04:00PM  
May-31-20 08:27PM  
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb clinical trial to treat ulcerative colitis; SER-401, which is in Phase Ib clinical trial for use with checkpoint inhibitors in patients with metastatic melanoma; and SER-301 that is in the Phase 1b clinical trial for the treatment of inflammatory bowel disease. In addition, the company engages in the development of SER-262 to treat an initial recurrence of CDI; and SER-155, a cultivated bacteria microbiome drug designed to prevent mortality due to gastrointestinal infections, bacteremia, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Henn Matthew R.See RemarksDec 01Option Exercise5.5679,812443,72091,812Dec 03 04:05 PM
Henn Matthew R.See RemarksDec 01Sale27.0491,8122,482,3090Dec 03 04:05 PM